Hexima Past Earnings Performance

Past criteria checks 0/6

Hexima's earnings have been declining at an average annual rate of -8.2%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 4% per year.

Key information

-8.2%

Earnings growth rate

10.9%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate-4.0%
Return on equity-29.6%
Net Margin-388.5%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?

Mar 21
Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Sep 06
Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Read This Before Selling Hexima Limited (ASX:HXL) Shares

Mar 02
Read This Before Selling Hexima Limited (ASX:HXL) Shares

Revenue & Expenses Breakdown
Beta

How Hexima makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:HXL Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-100
30 Sep 231-110
30 Jun 231-221
31 Mar 233-534
31 Dec 225-848
30 Sep 225-9410
30 Jun 226-10311
31 Mar 225-9310
31 Dec 215-839
30 Sep 214-839
30 Jun 214-728
31 Mar 213-626
31 Dec 203-515
30 Sep 203-414
30 Jun 202-414
31 Mar 203-414
31 Dec 193-414
30 Sep 193-314
30 Jun 193-315
31 Mar 194-215
31 Dec 184-215
30 Sep 184-215
30 Jun 184-215
31 Mar 184-215
31 Dec 174-215
30 Sep 174-214
30 Jun 174-214
31 Mar 174-215
31 Dec 165-215
30 Sep 165-215
30 Jun 165-215
31 Mar 165-215
31 Dec 155-115
30 Sep 155-215
30 Jun 155-214
31 Mar 155-215
31 Dec 145-325
30 Sep 145-215
30 Jun 144-214
31 Mar 144-314
31 Dec 134-314
30 Sep 134-314
30 Jun 133-314
31 Mar 134-214

Quality Earnings: HXL is currently unprofitable.

Growing Profit Margin: HXL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HXL is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.

Accelerating Growth: Unable to compare HXL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HXL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.3%).


Return on Equity

High ROE: HXL has a negative Return on Equity (-29.6%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.